Vanguard Group’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-1,932,683
| Closed | -$29M | – | 4135 |
|
|
2016
Q2 | $29M | Buy |
1,932,683
+6,913
| +0.4% | +$88.8K | ﹤0.01% | 2163 |
|
|
2016
Q1 | $23.4M | Buy |
1,925,770
+169,095
| +10% | +$2.37M | ﹤0.01% | 2229 |
|
|
2015
Q4 | $27.9M | Buy |
1,756,675
+58,822
| +3% | +$926K | ﹤0.01% | 2154 |
|
|
2015
Q3 | $26M | Buy |
1,697,853
+15,921
| +0.9% | +$344K | ﹤0.01% | 2172 |
|
|
2015
Q2 | $40.9M | Sell |
1,681,932
-7,263
| -0.4% | -$174K | ﹤0.01% | 2042 |
|
|
2015
Q1 | $39.3M | Buy |
1,689,195
+87,468
| +5% | +$2.31M | ﹤0.01% | 2027 |
|
|
2014
Q4 | $40.2M | Buy |
1,601,727
+117,226
| +8% | +$3.44M | ﹤0.01% | 1947 |
|
|
2014
Q3 | $46.2M | Buy |
1,484,501
+194,579
| +15% | +$5.27M | ﹤0.01% | 1837 |
|
|
2014
Q2 | $33.4M | Buy |
1,289,922
+11,557
| +0.9% | +$257K | ﹤0.01% | 2027 |
|
|
2014
Q1 | $29.9M | Buy |
1,278,365
+106,726
| +9% | +$2.33M | ﹤0.01% | 2050 |
|
|
2013
Q4 | $29.7M | Buy |
1,171,639
+100,947
| +9% | +$2.28M | ﹤0.01% | 2021 |
|
|
2013
Q3 | $21.8M | Buy |
1,070,692
+390,219
| +57% | +$8.69M | ﹤0.01% | 2076 |
|
|
2013
Q2 | $14.3M | Buy |
+680,473
| New | +$12.2M | ﹤0.01% | 2186 |
|
Vanguard Group's SGNT Position: Q3 2016 in Review
Vanguard Group sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 1,932,683 shares — an estimated $29M sold.
Vanguard Group first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $46.2M in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- Vanguard Group reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- Vanguard Group sold 1,932,683 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $29M.
- Vanguard Group first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- Vanguard Group's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $46.2M in Q3 2014.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on Vanguard Group's 13F filing for Q3 2016, filed 14 Nov 2016.